In an interview to CNBC-TV18, Manish Gupta, CEO, Sequent Scientifics, said that it has been a strategic acquisition, which fast-tracks the company foray into the global arena.
In an interview to CNBC-TV18, Manish Gupta, CEO, Sequent Scientifics, said that it has been a strategic acquisition, which fast-tracks the company foray into the global arena.
Besides providing a strong presence in Turkey, the deal gives Sequent an opportunity to expand in other markets like Central and Eastern Europe and Russia, Gupta said.
The acquisition also gives the company access to Provet's 100-odd products, which it can leverage and expand into other territories. These include injectibles, intra-mammaries suspensions and oral solutions. And finally, it brings manufacturing capability to the table.
Sequent Scienti stock price
On September 11, 2014, at 14:10 hrs Sequent Scientific was quoting at Rs 500.00, up Rs 16.05, or 3.32 percent. The 52-week high of the share was Rs 507.95 and the 52-week low was Rs 125.00.
The latest book value of the company is Rs -4.74 per share. At current value, the price-to-book value of the company was -105.49.
Anda sedang membaca artikel tentang
Sequent Scientific arm Alvira buys 60% in Turkey's Provet
Dengan url
https://kesehatanda.blogspot.com/2014/09/sequent-scientific-arm-alvira-buys-60.html
Anda boleh menyebar luaskannya atau mengcopy paste-nya
Sequent Scientific arm Alvira buys 60% in Turkey's Provet
namun jangan lupa untuk meletakkan link
Sequent Scientific arm Alvira buys 60% in Turkey's Provet
sebagai sumbernya
0 komentar:
Posting Komentar